Creative Graphics
Reliability Through Technology

Creative Graphics Solutions India Limited

(Formerly Known as Creative Graphics Solutions (I) Pvt. Ltd.)
Corporate office: A-31, Sector-58, Noida- 201301, Uttar Pradesh, India
Registered office: 3F-305, 3rd Floor, SSG East Plaza, Plot No. 1 & 2,
Mamram Complex, Mayur Vihar, Phase-III, Delhi- 110096, India
E-mail Id: accounts@creativegraphics.net.in, Mob:9560799003
CIN: L22219DL2014PLC263964

Date: 14-11-2026

The Head- Listing Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C-1, G Block,
Bandra-Kurla Complex
Mumbai - 400 051

NSE Symbol: CGRAPHICS

Subject: ***Investor Presentation for the half year ended September 30, 2026***

Dear Sir/Madam,

With reference to the captioned subject, please find enclosed the Management's Presentation for the Earnings Conference Call with analysts/ Investors scheduled for **Wednesday, November 18, 2026** in relation to the unaudited financial results (Standalone and Consolidated) for the half-year ended September 30, 2026.

Kindly take the above-said information on record.

Yours sincerely,
For Creative Graphics Solutions India Limited

SHRAVYA SRIVASTAVA

Digitally signed by SHRAVYA SRIVASTAVA
DN: c=IN, o=Personal, postalCode=226002, l=Lucknow, st=Uttar Pradesh, street=MI Retreat Center1, B3 Emerald, Flat number 403 Plot No 783, Sarsawan, Arjunganj, Lucknow, Uttar Pradesh India 226002, title=8826, 2.5.4.20=2eee845e7325e38f86a428ee9d70bb8fd5cbde68afc2560f92df4611b27937a2, serialNumber=1f9276314 1a87ba8becb2944a7d258e40be3179 7c05c40ac279fa0010382ffb2, email=shravyasit@gmail.com, cn=SHRAVYA SRIVASTAVA
Date: 2026.11.14 21:15:20 +05'30'

Shravya Srivastava
Company Secretary & Compliance Officer

Creative Graphics
Reliability Through Technology

Earnings Presentation

H1 FY27

Half-year ended 30 September 2026









Creative Graphics Solutions India Limited
NSE: CGRAPHICS

Safe harbour and disclaimers

- **Purpose:** The information is provided by Creative Graphics Solutions India Limited ("Company") for informational purposes only. It does not constitute an offer, solicitation, or invitation to buy or sell any securities or to make any investment decisions. The content is not a recommendation or part of any contract.
- **No Prospectus:** This presentation does not serve as a prospectus or offer document under any applicable laws or regulations, including but not limited to the Companies Act, 2013, or the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended from time to time.
- **Disclaimer of Liability:** No representation or warranty is made regarding the accuracy, completeness, or fairness of the information. The Company and its affiliates are not liable for any losses arising from the use of this presentation. Information may be subject to change without obligation to update.
- **Forward-Looking Statements:** This presentation may contain forward-looking statements based on current beliefs and assumptions. These statements involve risks and uncertainties that could cause actual results to differ materially. Industry and market data are derived from sources believed to be reliable but are not independently verified.
- **Not an Offer:** This presentation is not an offer to sell or a solicitation to buy securities in India, the United States, or any other jurisdiction.

Creative Graphics
Reliability Through Technology


01

Company and strategy overview

Creative Graphics at a glance

Flexography

Creative Graphics Solutions India Limited · listed parent



Flexographic printing

Creative Graphics makes the photopolymer printing plates that carry brand artwork onto film, foil, paper and board. Its prepress and colour engineering teams prepare each design for print, serving FMCG, food, pharma and industrial packaging.

Pharmaceutical packaging

Wahren India Private Limited · 100% subsidiary



Wahren production line

Wahren makes high-barrier primary packaging that protects tablets and capsules from moisture, oxygen, light and contamination: cold-form Alu Alu and blister lidding foils, PVC/PVDC films and extrusion laminates, from one audit-ready supplier.

Presence: nine flexo plants and globally sourced pharma lines

Pharma packaging (Wahren)

Production lines and their source countries



IT **Bobst EXPERTCOAT 1000** Italy
Alu Alu foil: precision coating and lamination; takes Alu Alu capacity to 20,000 MT


DE **PVDC coating line** Germany
PVC/PVDC films: four-stage coating, 30 to 180 GSM; 12,000 MT

KR **Tandem extrusion line** South Korea
Extrusion laminates: dual-stage, 3 to 5 ply; 12,000 MT

IN **HSL coating machine** India
Heat-seal coated lidding foil with uniform coating and strong peel strength

Flexography

Nine plants across India and Oman



8	7	12+	4,350+	44,000 MTPA	497
Indian cities	states	countries served	active clients	pharma capacity	employees

Oman plant installed in FY26; commercial start pending. Kolkata is a joint-venture plant and is not included in the plant counts. Active clients: 4,000+ flexography and 350+ pharma packaging. Employees on the Company's payroll at 31 March 2026.

From a flexo plate maker to a ₹346 Cr packaging group

Creative Graphics
Reliability Through Technology

Phase 1 | Early 2000s to FY22


Building the flexo base

- **Early 2000s** — Founder starts the flexo plate business
- **2014** — Company incorporated; Vasai (Mumbai) plant added to Noida
- **2017** — Chennai, through the acquisition of Color Dot Madras
- **2018** — Baddi, through the acquisition of Bwin Digiflex; Hyderabad plant
- **2021** — Ahmedabad plant; CG Premedia launched for design and prepress
- **2022** — Pune plant: seven plants serving FMCG, food and pharma brands

₹68.3 Cr
FY22 revenue from flexo plates and premedia

Phase 2 | FY22 to FY26

Multiplying with pharma packaging



PAT **₹4.7 Cr → ₹18.8 Cr**

Growth drivers

Pharma packaging
Wahren started production in 2023 adding significant contribution to the revenue

Standalone business
Revenue reached ₹155 Cr in FY26, up 38.9%, with Bengaluru added


Capital
Listed on NSE Emerge in April 2024; IPO proceeds funded working capital

Revenue and PAT are consolidated. FY26 business revenue is entity-level; Creative Graphics standalone includes sales to Wahren, eliminated on consolidation.

The first transition is complete; the next is underway

01 | Transition achieved

From one business to two



In just over three years, pharma packaging has become the larger revenue contributor, built on the Group's strengths in precision manufacturing, quality systems and compliance.

02 | Next phase under execution

Both businesses are expanding

Flexography | geographical expansion

Take the proven platform to more markets

- Bengaluru operational
- Oman manufacturing footprint established
- Wider domestic and international reach

Pharma packaging | product portfolio expansion

Build a multi-product packaging portfolio

- Alu Alu foil → PVC/PVDC films, Extrusion laminates, Sachets, Strip foils, Blister foils, Child-resistant formats

Both businesses are expanding together: flexography by geography, pharma packaging by product depth.

Four reasons behind our entry into pharma packaging

Creative Graphics
Reliability Through Technology

WAHREN
Protects . Preserves

Entering pharma packaging

01
A quality-led market

India's growing pharma sector needs reliable, compliance-ready primary packaging made at scale

02
Ready customer access

Flexo plates already served pharma companies, shortening Wahren's customer acquisition cycle

03
Throughput economics

Moderate percentage margins, but higher volumes lift absolute contribution and asset turnover as utilisation rises

04
Capital-efficient entry

PVC/PVDC and Tandem lines acquired through an NCLT process at about 10% of estimated replacement cost

Built on the Group's strengths in precision manufacturing, quality systems and compliance

Strategic priorities: turning new capacity into earnings

With capex complete, the next phase is about higher utilisation, a broader product portfolio and a rising export contribution

Priority	Focus	Progress so far
Fill the new capacity	Raise utilisation of 44,000 MTPA of pharma capacity and the new flexo plants, so fixed costs are spread over more output	All three new pharma lines in production since October 2026; Bengaluru flexo plant in its first full half-year
Broaden the pharma portfolio	Serve pharma clients across their primary packaging needs from one relationship	PVC/PVDC and Tandem lines added to Alu Alu; DMFs in the USA, China and Canada
Build the export business	Grow exports towards about 25% of pharma packaging revenue, offering overseas buyers credit terms through export factoring	First export order in February 2026; ₹8.3 Cr of pharma exports in H1 FY27; export factoring in place since H1 FY27
Grow flexography in new regions	Extend the plate network into fast-growing markets, as EPR compliance continues to support flexo	Bengaluru flexo plant operational since August 2025; Oman plant installed as an entry point to the Middle East and Africa
Protect margins from input swings	A more structured buffer stock of key imported materials, and periodic price revisions that pass on part of input cost changes	Response to the H2 FY26 disruption in aluminium, PVC and PVDC supply

Creative Graphics
Reliability Through Technology


02

H1 FY27 financial performance

Consolidated financial performance, H1 FY27


Revenue ₹ Cr

+32.6% YoY



EBITDA ₹ Cr

−7.2% YoY




H1 FY26	H2 FY26	H1 FY27
11.9%	7.3%	8.3%

EBITDA margin

PAT ₹ Cr

−40.4% YoY



H1 FY26	H2 FY26	H1 FY27
6.9%	3.9%	3.1%

PAT margin

EBITDA below last year for two reasons, but up 57% on H2 FY26

New capacity still ramping up

All planned capex is complete, but volumes on the new lines and plants are still building. Employee and other expenses rose 45% year on year as they were staffed and run ahead of revenue, and the new Alu Alu line began commercial production only in October 2026.

Middle East conflict disrupted supply chains

The war in Middle East disrupted supply chains for key imported materials, delaying the ramp-up of PVDC and Tandem Plants and commercial start of the Oman flexo plant. Alu Alu business was also impacted by supply chain disruption in Q1, with a strong recovery in Q2 FY27.

Key performance drivers and highlights, H1 FY27

Revenue and exports

- Consolidated revenue of ₹233.3 Cr, up 32.6% year on year and 37.1% over H2 FY26
- Alu Alu was impacted by supply chain disruption in Q1, with a strong recovery in Q2
- Exports of ₹12.0 Cr, 5.2% of revenue despite the supply chain issues; already above the full-year FY26 total of ₹8.1 Cr
- 5 industry expos in H1 FY27 across India, Jordan, Egypt and Nigeria
- In discussion with customers in 11 countries for pharma packaging exports

Profitability

- EBITDA of ₹19.5 Cr at an 8.3% margin: up from 7.3% in H2 FY26, but below 11.9% a year ago as new capacity carries fixed costs ahead of volumes and the Middle East conflict disrupted supply chains

Capacity and operations

- All planned capex complete: 44,000 MTPA of pharma packaging capacity installed
- New 12,000 MT Alu Alu line: trials completed in August 2026; commercial production from October 2026

Customers and markets

- 400+ pharma customers
- Now targeting larger pharma customers

Funding

- CARE BBB; Stable issuer rating assigned on 12 October 2026
- Export factoring introduced to fund export receivables soon after shipment

₹233.3 Cr
Revenue, up 32.6% year on year

400+
Pharma customers

44,000 MTPA
Pharma capacity; all lines in production from October 2026

₹12.0 Cr
Exports in H1 FY27

Industry engagement and customer outreach, H1 FY27

5 industry events
FY26: 11

4 countries
FY26: 7

2 continents
FY26: 3

2 technical presentations
FY26: 2



Innopack Mumbai

June 2026

Mumbai, India



Arab Manufacturer

1 to 2 July 2026

Jordan



Innopack Hyderabad

20 to 21 August 2026

Hyderabad, India



Pharmaconex

1 to 3 September 2026

Egypt



Nigeria Pharma Expo

September 2026

Lagos, Nigeria


Earlier in 2026 (H2 FY26)

- **Pharmapack 2026** — Paris, 21 to 22 January
- **Nepal Pharma Expo 2026** — Kathmandu, 12 to 14 March
- **Asia Pharma Expo 2026** — Dhaka, 29 to 31 March

After the period (H2 FY27)

- **Caphex Pharma Expo** — Uzbekistan, 26 to 28 October
- **CPHI India** — India, 24 to 26 November (upcoming)

Flexo expansion: Bengaluru ramping up, Oman awaiting start




Bengaluru, Karnataka

In production

Opened August 2025; first full half-year in H1 FY27

- Serves the Bengaluru, Mangaluru and Coimbatore packaging corridor
- Brings plate-making closer to customers in one of South India's largest flexo markets
- Adds to a network of nine flexo plants: eight in India and one in Oman



Oman

Installed; start pending

First plant outside India

- Positioned at the gateway to Middle East and African markets
- Commercial start delayed by war-related supply chain and manpower challenges
- To serve packaging converters in the Gulf and Africa

Highlights

Closer to customers
Plate-making near converters in South India's packaging corridor

Access to the Gulf and Africa
First Creative Graphics plant outside India

Capex complete
Both plants are built and installed, with no further spending planned

New pharma lines: all three now in production

Pharma packaging capacity
MTPA, by line

Alu Alu 8,000	PVC/PVDC 12,000	Tandem 12,000	New Alu Alu 12,000	44,000



PVC/PVDC coating line Germany

PVC/PVDC films: four-stage coating, 30 to 180 GSM; 12,000 MT

Commercial production since H2 FY26



Tandem extrusion line South Korea

Extrusion laminates: dual-stage, 3 to 5 ply; 12,000 MT

Commercial production since April 2026



Bobst EXPERTCOAT 1000 Italy

Alu Alu foil: precision coating and lamination; 12,000 MT

Commercial production since October 2026

Also installed: HSL coating machine (India) for heat-seal coated lidding foil


Consolidated profit and loss statement

₹ Cr	H1 FY27	H1 FY26	YoY	H2 FY26	HoH	FY26
Revenue from operations	**233.3**	**175.9**	**+32.6%**	**170.1**	**+37.1%**	**346.0**
Cost of materials consumed	175.1	128.3	+36.5%	130.1	+34.6%	258.4
Gross profit	58.2	47.6	+22.2%	40.0	+45.4%	87.6
Gross margin	*24.9%*	*27.1%*	*−214 bps*	*23.5%*	*+142 bps*	*25.3%*
Employee benefits expense	18.1	12.8	+41.7%	15.8	+14.6%	28.6
Other expenses	20.6	13.9	+48.5%	11.8	+75.0%	25.7
EBITDA	**19.5**	**21.0**	**−7.2%**	**12.4**	**+56.6%**	**33.4**
EBITDA margin	*8.3%*	*11.9%*	*−358 bps*	*7.3%*	*+104 bps*	*9.7%*
Other income	0.1	1.0	−94.9%	2.0	−97.4%	3.0
Depreciation and amortisation	4.1	2.6	+60.9%	2.9	+40.1%	5.5
Finance costs	5.3	3.0	+77.6%	3.7	+43.5%	6.7
Profit before tax	**10.1**	**16.4**	**−38.5%**	**7.8**	**+30.2%**	**24.2**
Tax expense	2.8	4.2	−33.3%	1.2	+136.1%	5.4
Profit after tax	**7.3**	**12.2**	**−40.4%**	**6.6**	**+11.0%**	**18.8**
PAT margin	*3.1%*	*6.9%*	*−382 bps*	*3.9%*	*−74 bps*	*5.4%*
EPS, basic (₹)	3.00	5.03	−40.4%	2.70	+11.1%	7.72

Balance sheet: capex done, new debt funds working capital

Borrowings rose ₹37.4 Cr in H1 FY27 as receivables and inventory grew with a 33% rise in revenue; net worth reached ₹132.8 Cr

Net worth, ₹ Cr



Up ₹26.1 Cr since March 2025, all from retained profit, with no new equity issued

Capex
All planned capex complete

Working-capital limits
₹200 Cr, including ₹60 Cr from Citibank

CARE BBB; Stable

Credit rating
Issuer rating assigned by CARE Ratings on 12 October 2026

Summary balance sheet, ₹ Cr

Assets	Mar-26	Sep-26	Equity and liabilities	Mar-26	Sep-26
PP&E incl. CWIP	72.5	68.0	Net worth	125.5	132.8
Right-of-use assets	3.2	14.3	Long-term borrowings	29.9	14.7
Trade receivables	114.2	173.3	Short-term borrowings	62.0	114.5
Inventories	55.7	73.5	Lease liabilities	2.7	21.4
Cash and equivalents	9.2	9.6	Trade payables	46.1	75.7
Other assets	24.9	41.1	Other liabilities	13.5	20.7
Total assets	**279.7**	**379.8**	**Total**	**279.7**	**379.8**

Changes during H1 FY27

- Receivables up ₹59.2 Cr and inventories up ₹17.8 Cr as revenue grew 33%
- Borrowings up ₹37.4 Cr, all of it short-term, funding receivables and inventory
- Right-of-use assets up ₹11.0 Cr and lease liabilities up ₹18.7 Cr with new leases
- Net worth up ₹7.3 Cr from retained profit

₹ Cr, consolidated. Mar-25 and Mar-26 audited; Sep-25 and Sep-26 unaudited. Short-term borrowings include current maturities of long-term debt; other assets and other liabilities are the remaining balance sheet items.

Creative Graphics
Reliability Through Technology

03

Segmental overview and statistics

Group structure: a listed parent and two subsidiaries



Creative Graphics Solutions India Limited

Listed on NSE Emerge · Flexography

100%



Wahren India Private Limited

Pharmaceutical packaging · production since 2023

100%



CG Premedia Private Limited

Package design, artwork and prepress, mock-ups and 3D CGI

Flexography: an end-to-end plate and prepress business

Products

Digital plates
High-resolution plates imaged digitally for fine dots and colour consistency

Conventional plates
Analogue plates for standard, cost-sensitive jobs

Letterpress plates
Labels, pharma carton coding and speciality packs

Coating plates
UV spot coating and varnish for premium finishes

Business model

Converters order plates for each new design; brand owners set the artwork and colour standards. Colour management, proofing and press support come with the plate supply.

Plate-making process

Prepress — 200+ experts make each design file print-ready

Colour engineering — Colour software matches the brand's colours

Computer-to-plate — European imaging equipment, with no manual film step

Processing and dispatch — Developed, dried, finished and checked in-house

Applications

- FMCG pouches
- Food packaging
- Pharma cartons
- Industrial labels
- Corrugated board

4,000+ active clients


12+ countries served

Brands across FMCG, pharma, personal care and food; many relationships span a decade or more



Standalone business performance

Standalone revenue ₹ Cr



EBITDA margin

H1 FY25	H2 FY25	H1 FY26	H2 FY26	H1 FY27
15.9%	17.5%	18.6%	11.5%	12.5%

₹9.9 Cr
EBITDA (H1 FY26: ₹12.6 Cr)

₹5.5 Cr
PAT (H1 FY26: ₹7.7 Cr)

4,000+
active clients

12+
countries served

Principal drivers

- Revenue: up 17.3% year on year, helped by Bengaluru's first full half-year
- Costs: Bengaluru and Oman carry staff and fixed costs ahead of volumes
- Margin: 12.5%, up from 11.5% in H2 FY26 but below 18.6% a year ago

Wahren: high-barrier primary packaging for medicines

Protection requirements

Moisture **Oxygen** **Light** **Contamination**

Packaging preserves efficacy, safety and shelf life

Product portfolio, standard to highest barrier

Standard	High	Ultra-high	Highest
PVC film	PVC/PVDC film New	Ultra-high barrier films	Alu Alu cold-form foil

Also: blister lidding foils, including heat-seal coated (new) and child-resistant, and extrusion laminates (new) for sachets, strip foils and multi-layer packs

Exports: in discussion with customers in 11 countries

Pharma clients



350+ pharma clients · DMFs in the USA, China and Canada · GMP, ISO, BRC and SGS

Typical customer qualification path

Supplier audit	Trials on customer lines	Documentation and DMF reference	Vendor approval	Commercial and repeat orders
GMP, ISO, BRC and SGS systems	Forming and sealing on client machines	Specifications and regulatory files	Approved material and supplier	Batch-by-batch supply

Creative Graphics
Reliability Through Technology

04

Investment strengths

Five investment strengths

1 Two complementary businesses

Flexography and pharma packaging serve different markets, with different demand drivers



5 Export development

DMF-backed access; target of about 25% of pharma revenue from exports

2 Recurring demand

Packs are used up with every batch; 95%+ client retention

4 High entry barriers

Specialised lines, audited quality systems and DMFs in the USA, China and Canada

3 Capacity in place, capex complete

Pharma capacity up 5.5x to 44,000 MTPA; all planned capex is complete

1 Two complementary businesses, different demand drivers

Business profile

	Flexography	Pharma packaging
Demand driver	New designs, launches and plate wear	Medicine production, batch by batch
Order pattern	Plates for every new design, replaced as they wear	Fresh packs for every batch, on approved material
Products	Digital, conventional and letterpress plates; prepress	Alu Alu foils, PVC/PVDC films, extrusion laminates and lidding foils
Capacity	Nine plants: eight in India and one in Oman	44,000 MTPA across four lines
Entry barriers	Colour expertise, imaging technology and a national network	Audited quality systems, customer approvals and DMFs

4,350+
active clients across both businesses

12+
countries served


End-use application map

	Flexography	Pharma packaging
FMCG	●	
Food	●	○
Pharmaceuticals	●	●
Personal care	●	
Dairy	●	
Confectionery	●	
Beverages and alcohol	●	
Industrial labels	●	
Contraceptives		●

● main application ○ selected products

2 Demand recurs with every batch and every new design

Pharma packaging: every batch needs fresh packs



Flexography: continuous production and new designs



95%+ client retention, FY26

~6% a year projected market growth


~20% of global generics by volume made in India

3 Capacity in place to grow without major new capex

Pharma packaging capacity

5.5x

8,000 to 44,000 MTPA



From investment to output

1. **₹31.0 Cr**
   FY26 group capex; two lines bought at about 10% of replacement cost
2. **44,000 MTPA**
   installed pharma packaging capacity
3. **32,000 MTPA**
   in commercial production at 30 September 2026; all 44,000 MTPA from October 2026

Demand to fill the capacity

Larger customers
Now targeting larger pharma customers

New formats
PVC/PVDC films and Tandem laminates

Exports
Target of about 25% of pharma revenue


Sales team
Expanded; Head of Export Sales hired

Operating leverage the existing 8,000 MTPA Alu Alu capacity is already fully utilised; as the new lines fill, staff and depreciation costs are spread over more output, supporting margins and returns

₹1,000 Cr The platform is already built to support revenue of ₹1,000 Cr and beyond.

Capex is consolidated purchase of property, plant and equipment. MTPA = metric tonnes per annum.

4 Specialised assets and approvals raise entry barriers



A new entrant needs


1 Capital	2 Time	3 Expertise	4 Testing	5 Certification	6 Qualification
Imported coating, lamination and extrusion lines	Procurement, installation and trials	Material science and process control	In-house lab for strength, sealing and forming	GMP, ISO, BRC and SGS systems and DMFs	Audits and trials at every customer

Wahren today

1 Capital	2 Time	3 Expertise	4 Testing	5 Certification	6 Qualification
✓ Two lines acquired at about 10% of replacement cost	✓ New Alu Alu line delivered October 2025; trials completed in 2026	✓ Team skilled in prepress, packaging and material science	✓ Lab tests tensile and bond strength, heat sealability, GSM and thickness	✓ GMP, ISO, BRC and SGS; DMFs in the USA, China and Canada	✓ 350+ active pharma clients

The PVC/PVDC and Tandem lines were acquired through an NCLT process at about 10% of estimated replacement cost. DMF = Drug Master File.

5 Export development broadens the addressable market



● DMF markets ● Export markets ○ Oman plant, start pending

Export path

FY26 ₹8.1 Cr of exports, 2.3% of group revenue; first pharma export order in February 2026

H1 FY27 ₹12.0 Cr of exports, 5.2% of revenue: Wahren ₹8.3 Cr and flexography ₹3.7 Cr

Target **About 25% of pharma packaging revenue from exports**

Target customers

- **Generic drug makers serving regulated markets** Can reference Wahren's DMFs in their filings
- **Pharma companies in the Middle East, Africa and Asia** Markets where the Company exhibited in FY26
- **Packaging converters in the Gulf and Africa** To be served from the Oman flexo plant

- DMFs in the USA, China and Canada
- First pharma export order in February 2026; export factoring now in place
- Exports earn better price realisations than domestic sales

DMF = Drug Master File.

A founder-led board with an experienced leadership team

Board of directors



Mr. Deepanshu Goel
Founder and Managing Director

Has built the business since 1998 and led its move into pharma packaging. Hindu College (DU); IIM Lucknow



Mrs. Sarika Goel
Executive Director

Shapes strategy and a culture of learning and skill development. Delhi University graduate



Mr. Gaurav Arora
Non-Executive Non-Independent Director

Eight years in executive roles with ENI Saipem across Europe, Africa and Southeast Asia



Mr. Nikhil Rungta
Independent Director

25+ years in CXO roles at Google, Intuit, Yahoo, Reliance Jio, Housing.com and Yatra.com



Mr. Puneet Sharma
Independent Director

25+ years in finance and strategy at GE Capital, HSBC and TCS. MBA in finance; IFRS certified

Key managerial personnel



Mr. Muhammad Rafeeq M
Chief Executive Officer, Flexo

30+ years in printing, packaging and prepress across India and the Middle East; DuPont, Esko-Graphics, Obeikan



Mr. Pulkit Agrawal
Group Chief Financial Officer

CFA charterholder with 15+ years at Fidelity Investments, Engie and Karma Capital. MBA, XIMB



Ms. Shravya Srivastava
Company Secretary and Compliance Officer

Qualified company secretary; previously with Tata 1mg and a practising company secretary firm

Board at a glance


5
Directors on the Board

40%
Independent directors

20%
Women directors

4
Board committees

Committees: Audit · Nomination and remuneration
CSR · Stakeholder relationship



Thank you

Earnings Presentation, H1 FY27

Investor contacts

For further details, please feel free to contact the investor relations team

Creative Graphics Solutions India Limited
Email: cs@creativegraphics.net.in
Web: www.creativegraphics.net.in
Phone: 0120-6836051

Vogabe Advisors Private Limited
Himani Singla / Nikhil Kansal
Mobile: 9569926021
Email: hs@vogabe.com / nik@vogabe.com